Industry Newsroom

TPG Growth Leads USD125m Series C for India’s Stelis Biopharma

TPG Growth led a USD125m Series C for Stelis Biopharma, the biopharmaceutical unit of Mumbai-listed Strides Pharma Science, with participation from Route One, Think Investments and Mankekar Family. Strides also announced that Stelis closed a USD70m Series B, bringing total capital raised across the latest funding rounds to USD195m. Read more